Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Boring Dividend Stocks to Buy. On Novemb‍er 24, Truist’​s‍ Gregor‌y Ren⁠za in​itiated coverage of Gilead Sciences, Inc. (NASDAQ:GILD) ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...

Deutsche Bank upgraded Gilead (GILD) to Buy from Hold with a price target of $120, up from $80. The company’s core HIV treatment franchise should drive steady revenue growth deep into to the 2030s, ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed yesterday at $103.31. Leverage the power of TipRanks' Smart ...

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster of ...

How much is a fast track for the Food and Drug Administration review of a new drug worth? Try $125 million. In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon ...

Since it’s a publicly traded company, anyone can buy Gilead Sciences stock. Here’s a step-by-step guide on how to invest money in the pharmaceutical stock: Step 1: Open your brokerage account: Log in ...

Gilead is down 16% from its recent high in a strong market. This seems warranted given the analyst estimates for the coming years. However, Gilead is investing heavily into R&D and made a promising ...

(Reuters) - Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class ...

There's no question that Gilead can afford to make more deals. The big biotech reported $36.7 billion in cash, cash equivalents, and marketable securities at the end of 2017. Gilead also has ample ...